As of March 31, 2023, Intercept had cash, cash equivalents, restricted cash, and investment debt securities available for sale of $435.2 million. As of December 31, 2022, Intercept had cash, cash equivalents, restricted cash, and investment debt securities available for sale of approximately $490.9 million. As anticipated, the company experienced revenue seasonality and higher cash utilization in the first quarter of 2023 relative to what is seen in other quarters.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ICPT:
- Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH
- Intercept Announces New Data to be Presented at The European Association for the Study of the Liver (EASL) Congress 2023 and Provides Update on OCA-bezafibrate Fixed-Dose Combination (FDC) Development Program
- Is ICPT a Buy, Before Earnings?
- Piper Sandler pharmaceuticals analysts to hold analyst/industry conference call
- Intercept to Announce First Quarter 2023 Financial Results and Provide Update on Commercial Launch Strategy for NASH on April 27, 2023
